Searchable abstracts of presentations at key conferences in endocrinology

ea0050p387 | Thyroid | SFEBES2017

The Oxford Multidisciplinary Thyroid Eye Disease Clinic: Can short waiting times and use of Steroid Sparing Agents reduce total glucocorticoid dose and requirement for surgery/radiotherapy?

Turner Helen , David Joel , Norris Jonathan

Introduction: The Oxford multidisciplinary thyroid eye disease (TED) clinic comprising an oculoplastic surgeon, rheumatologist and endocrinologist with access to orthoptics, neuroradiology and radiotherapy was established in 2013. The aim of the service is to facilitate rapid referral and treatment in a specialist centre in keeping with the Amsterdam Declaration. Early use of steroid sparing agents (SSA) and recently rituximab form part of the treatment regimen.<...

ea0050p387 | Thyroid | SFEBES2017

The Oxford Multidisciplinary Thyroid Eye Disease Clinic: Can short waiting times and use of Steroid Sparing Agents reduce total glucocorticoid dose and requirement for surgery/radiotherapy?

Turner Helen , David Joel , Norris Jonathan

Introduction: The Oxford multidisciplinary thyroid eye disease (TED) clinic comprising an oculoplastic surgeon, rheumatologist and endocrinologist with access to orthoptics, neuroradiology and radiotherapy was established in 2013. The aim of the service is to facilitate rapid referral and treatment in a specialist centre in keeping with the Amsterdam Declaration. Early use of steroid sparing agents (SSA) and recently rituximab form part of the treatment regimen.<...

ea0049gp203 | Thyroid 1 | ECE2017

The oxford multidisciplinary thyroid eye disease (TED) clinic; can short waiting times and use of steroid sparing agents (SSA) reduce total steroid dose and requirement for surgery/radiotherapy?

Turner Helen , David Joel , Norris Jonathan

Introduction: The Oxford multidisciplinary thyroid eye disease (TED) clinic comprising an oculoplastic surgeon, rheumatologist and endocrinologist with access to orthoptics, neuroradiology and radiotherapy was established in 2013. The aim was to facilitate rapid referral and treatment in a specialist centre in keeping with Amsterdam Declaration. Early use of steroid sparing agents (SSA) and recently rituximab forms part of the treatment regimen.Methods: ...

ea0049gp206 | Thyroid 2 | ECE2017

Early use of steroid-sparing agents in treatment of moderate-to-severely active thyroid eye disease

Sipkova Zuzana , David Joel , Turner Helen , Norris Jonathan

Introduction: The management of active thyroid eye disease (TED) remains controversial. High dose intravenous methylprednisolone (IVMP) is the current recommended first-line treatment based on EUGOGO guidance. Such therapy has the potential for serious adverse effects. We present the outcomes of an alternative approach in the management of moderate-to-severely active TED, using steroid-sparing agents (SSAs) in conjunction with IVMP. Methotrexate is used as the first-line SSA a...

ea0056gp260 | Thyroid non cancer - Autoimmune Thyroid disease/pregnancy | ECE2018

Early low dose rituximab for active thyroid eye disease: an effective and well tolerated treatment

Insull Elizabeth , Turner Helen , David Joel , Norris Jonathan

Background: Thyroid eye disease (TED) is an autoimmune inflammatory disease that can be both disfiguring and potentially sight threatening. Suppression of inflammation in active disease can reduce the risk of visual loss and limit long-term sequelae of the disease. Current disease management involves suppression of inflammation using glucocorticoids. The aim of our study was to evaluate the efficacy of early disease intervention with targeted immunomodulatory therapy to alter ...

ea0094p279 | Thyroid | SFEBES2023

Concurrent Myasthenia gravis (MG) and Graves’ ophthalmopathy (GO)

Naughton Aoife , Oustabassidis Eva , David Joel , Norris Jonathan , Turner Helen

Myasthenia gravis (MG) and Graves’ ophthalmopathy (GO) share many clinical characteristics but may also co-exist. Both are autoimmune disorders mediated by organ specific pathogenic autoantibodies to membrane surface receptors. Differential diagnosis and/or co-existence provides a potential management challenge, and there is a paucity of demographic information regarding precise prevalence rates and concurrence of disease.Method: Re...

ea0086p132 | Thyroid | SFEBES2022

Reconsidering the role of thyroidectomy in thyroid eye disease (TED) patients

Sipkova Zuzana , Keren Shay , David Joel , Mihai Radu , Turner Helen , Norris Jonathan

Purpose: Graves’ disease is an autoimmune condition that can cause hyperthyroidism and thyroid eye disease (TED). Definitive treatment is required in approximately 50% patients. Thyroidectomy remains the least chosen primary treatment (2%-18%) despite it having the highest cure rate (>95%). Our aim was to determine the current relationship between patients’ TED and thyroidectomy in a multidisciplinary specialist eye clinic at a tertiary referral centre.<p cla...

ea0086p290 | Thyroid | SFEBES2022

Late relapse of thyroid eye disease (TED)

Murphy Noel , Oustabassidis Eva , David Joel , Norris Jonathan H , Turner Helen E

Generally, after an initial active phase TED rarely reactivates. However, epidemiological evidence is scant. The following cases highlight the propensity for Graves’ orbitopathy to reactivate many years later.Case 1: A 69-year-old woman had Graves’ disease aged 29, and was reviewed in the TED clinic (ophthalmology, rheumatology and endocrinology), with reactivation of orbitopathy 40 years after initial disease. She was an ex-smoker, had hyperte...

ea0059p209 | Thyroid | SFEBES2018

Low dose rituximab for thyroid eye disease: an effective treatment with fall in TSH receptor antibodies (TRAb)

Suarez Annabel , Keren Shay , Norris Jonathan , David Joel , Turner Helen E

Background: Thyroid eye disease (TED) is an autoimmune inflammatory disease associated with Graves’ disease. Rituximab (a monoclonal antibody that depletes B-cells), has recently been shown to be effective in treating TED. There is evidence to support an association with increased TRAbs and TED severity, and one study has demonstrated a fall in TRAbs with rituximab therapy. The aim of this study was to assess the clinical efficacy of low dose rituximab in patients with TE...

ea00100p17 | Poster Presentations | SFEEU2024

‘Don’t forget the eye when seeing thyroid!’

Humayun Khan Huma , Oustabassidis Eva , Norris Jonathan , David Joel , Elizabeth Turner Helen

Case History with Investigations: A 65-year-old female, with no previous thyroid abnormalities, was originally referred to ENT with goitre. She was clinically and biochemically euthyroid, and following ultrasound with fine needle aspiration for right-sided nodules with benign cytology, was discharged. She was subsequently referred to Endocrinology with persistent lethargy and hair loss despite normal thyroid function. She described gritty eyes and swollen eyelids for 2 years, ...